Evidence map›Paper›PMID 42134322›Full record

ArticleCell stem cell2026

Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation.

Lei Lei, Masako M Kaufmann, Jessica Lao, Gudrun Thoulass, Sandra Ammann, Hui Xiao, Manuel Rhiel, Viviane Dettmer-Monaco, Julian Grünewald, Geoffroy Andrieux and 13 more

Abstract read
In one paragraph

Article in Cell stem cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lei LeiInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; PhD Program, Faculty of Biology, University of Freiburg, 79106 Freiburg, Germany.
Masako M KaufmannInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Spemann Graduate School in Biology and Medicine, University of Freiburg, 79104 Freiburg, Germany.
Jessica LaoCenter for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; PhD Program, Faculty of Biology, University of Freiburg, 79106 Freiburg, Germany; Institute for Immunodeficiency, Medical Center - University of Freiburg, 79104 Freiburg, Germany.
Gudrun ThoulassCenter for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; PhD Program, Faculty of Biology, University of Freiburg, 79106 Freiburg, Germany; Institute for Immunodeficiency, Medical Center - University of Freiburg, 79104 Freiburg, Germany.
Sandra AmmannInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Institute for Immunodeficiency, Medical Center - University of Freiburg, 79104 Freiburg, Germany.
Hui XiaoDepartment of Pediatric Hematology and Oncology, Medical Center - University of Freiburg, 79106 Freiburg, Germany.
Manuel RhielInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany.
Viviane Dettmer-MonacoInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany.
Julian GrünewaldMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, Boston, MA 02129, USA; Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, 79106 Freiburg, Germany; German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, 79106 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Jamal AlzubiInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic; Department of Haematooncology, University Hospital Ostrava, 70300 Ostrava, Czech Republic.
Bret R MillerMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, Boston, MA 02129, USA.
Kristoffer WeißertCenter for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Institute for Immunodeficiency, Medical Center - University of Freiburg, 79104 Freiburg, Germany.
Linda GräßelGerman Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, 79106 Freiburg, Germany; Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, 79106 Freiburg, Germany.
Christoph SchellFaculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; Institute of Surgical Pathology, Medical Center - University of Freiburg, 79106 Freiburg, Germany.
Anna L IllertGerman Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, 79106 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, 79106 Freiburg, Germany.
J Keith JoungMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, Boston, MA 02129, USA; Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
Melanie BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, 79106 Freiburg, Germany; German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, 79106 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Tatjana I CornuInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Stephan EhlCenter for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Institute for Immunodeficiency, Medical Center - University of Freiburg, 79104 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; CIBSS - Centre for Integrated Biological Signalling Studies, 79104 Freiburg, Germany.
Miriam ErlacherDepartment of Pediatric Hematology and Oncology, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; Department of Pediatrics and Adolescent Medicine, Medical Center - University of Ulm, 89075 Ulm, Germany.
Peter AicheleCenter for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Institute for Immunodeficiency, Medical Center - University of Freiburg, 79104 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Toni CathomenInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106 Freiburg, Germany; German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, 79106 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany. Electronic address: toni.cathomen@uniklinik-freiburg.de.

Funding

Evolution, Optimization, and Application of Genome Editing TechnologiesR35GM118158 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI JOUNG, J. KEITH · 2016 to 2023
$4.7M
NIGMS NIH HHS R35 GM118158
6 · The paper itself

Abstract

Base editors enable precise correction of point mutations without requiring DNA double-strand breaks, yet platform- and cell type-specific genotoxicities remain incompletely characterized. Here, we applied cytosine base editing (CBE) to disrupt a cryptic splice-site mutation in the Unc13d locus of Jinx mice, a model of familial hemophagocytic lymphohistiocytosis type 3 (FHL3). Efficient editing (62%-89%) in fibroblasts, T cells, and hematopoietic stem cells (HSCs) restored Unc13d splicing, reconstituted cytotoxic T cell function, and protected mice from virus-triggered hyperinflammation after transplantation of edited HSCs. Comparative genotoxicity profiling revealed distinct platform- and cell type-specific patterns: hyperactive CBE induced broader off-target activity and more structural variants than CRISPR-Cas9. Although off-target sequence edits persisted, the stability of CBE-induced chromosomal translocations differed between cell types. These findings establish base editing as a therapeutic strategy for a genetically predisposed hyperinflammatory syndrome and underscore the importance of context-specific safety profiling to guide the clinical translation of genome editors.

Indexed as

Gene EditingGenetic TherapyInflammationAnimalsCRISPR-Cas SystemsHematopoietic Stem CellsHumansMiceMutagenicity Testsbase editingCAST-seqCRISPR-Cascytosine base editorcytotoxicityFHL type 3genotoxicityhematopoietic stem cell transplantationhyperinflammationoff-target effects

Identifiers

PMID42134322
PMCPMC13188852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.